Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California. more
Time Frame | GERN | Sector | S&P500 |
---|---|---|---|
1-Week Return | -1.51% | -2.82% | 0.15% |
1-Month Return | -1.26% | -4.22% | 1.78% |
3-Month Return | -11.91% | -9.52% | 8.7% |
6-Month Return | -22.99% | -3.45% | 12.24% |
1-Year Return | 98.98% | 5.62% | 30.9% |
3-Year Return | 194.74% | 3.8% | 30.19% |
5-Year Return | 161.33% | 39.68% | 91.72% |
10-Year Return | 20.99% | 105.02% | 203.2% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 460.00K | 253.00K | 1.39M | 596.00K | 237.00K | [{"date":"2019-12-31","value":33.02,"profit":true},{"date":"2020-12-31","value":18.16,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":42.79,"profit":true},{"date":"2023-12-31","value":17.01,"profit":true}] |
Cost of Revenue | 39.26M | 50.05M | 783.00K | 868.00K | 123.74M | [{"date":"2019-12-31","value":31.73,"profit":true},{"date":"2020-12-31","value":40.45,"profit":true},{"date":"2021-12-31","value":0.63,"profit":true},{"date":"2022-12-31","value":0.7,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 460.00K | (49.80M) | 610.00K | (272.00K) | (123.50M) | [{"date":"2019-12-31","value":75.41,"profit":true},{"date":"2020-12-31","value":-8163.77,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-44.59,"profit":false},{"date":"2023-12-31","value":-20246.39,"profit":false}] |
Gross Margin | 100.00% | (19683.40%) | 43.79% | (45.64%) | (52110.97%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-19683.4,"profit":false},{"date":"2021-12-31","value":43.79,"profit":true},{"date":"2022-12-31","value":-45.64,"profit":false},{"date":"2023-12-31","value":-52110.97,"profit":false}] |
Operating Expenses | 72.97M | 77.17M | 115.39M | 139.15M | 194.18M | [{"date":"2019-12-31","value":37.58,"profit":true},{"date":"2020-12-31","value":39.74,"profit":true},{"date":"2021-12-31","value":59.42,"profit":true},{"date":"2022-12-31","value":71.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (72.50M) | (76.91M) | (114.00M) | (138.55M) | (193.94M) | [{"date":"2019-12-31","value":-7250500000,"profit":false},{"date":"2020-12-31","value":-7691300000,"profit":false},{"date":"2021-12-31","value":-11399900000,"profit":false},{"date":"2022-12-31","value":-13855000000,"profit":false},{"date":"2023-12-31","value":-19394400000,"profit":false}] |
Total Non-Operating Income/Expense | 8.18M | 2.36M | (5.33M) | (7.70M) | 19.66M | [{"date":"2019-12-31","value":41.6,"profit":true},{"date":"2020-12-31","value":12.03,"profit":true},{"date":"2021-12-31","value":-27.09,"profit":false},{"date":"2022-12-31","value":-39.19,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (68.55M) | (75.62M) | (116.11M) | (141.90M) | (184.13M) | [{"date":"2019-12-31","value":-6854800000,"profit":false},{"date":"2020-12-31","value":-7561700000,"profit":false},{"date":"2021-12-31","value":-11611200000,"profit":false},{"date":"2022-12-31","value":-14190100000,"profit":false},{"date":"2023-12-31","value":-18412700000,"profit":false}] |
Income Taxes | (5.00M) | (7.00K) | 4.84M | (868.00K) | 1.00 | [{"date":"2019-12-31","value":-103.24,"profit":false},{"date":"2020-12-31","value":-0.14,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-17.93,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (63.55M) | (75.61M) | (120.95M) | (141.03M) | (184.13M) | [{"date":"2019-12-31","value":-6355100000,"profit":false},{"date":"2020-12-31","value":-7561000000,"profit":false},{"date":"2021-12-31","value":-12095200000,"profit":false},{"date":"2022-12-31","value":-14103300000,"profit":false},{"date":"2023-12-31","value":-18412700100,"profit":false}] |
Income From Continuous Operations | (68.35M) | (75.68M) | (116.11M) | (141.90M) | (184.13M) | [{"date":"2019-12-31","value":-6835300000,"profit":false},{"date":"2020-12-31","value":-7567700000,"profit":false},{"date":"2021-12-31","value":-11611200000,"profit":false},{"date":"2022-12-31","value":-14190100000,"profit":false},{"date":"2023-12-31","value":-18412700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (63.55M) | (75.61M) | (120.95M) | (141.03M) | (184.13M) | [{"date":"2019-12-31","value":-6355100000,"profit":false},{"date":"2020-12-31","value":-7561000000,"profit":false},{"date":"2021-12-31","value":-12095200000,"profit":false},{"date":"2022-12-31","value":-14103300000,"profit":false},{"date":"2023-12-31","value":-18412700000,"profit":false}] |
EPS (Diluted) | (0.36) | (0.27) | (0.36) | (0.36) | (0.33) | [{"date":"2019-12-31","value":-36,"profit":false},{"date":"2020-12-31","value":-27,"profit":false},{"date":"2021-12-31","value":-36,"profit":false},{"date":"2022-12-31","value":-36,"profit":false},{"date":"2023-12-31","value":-33,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
GERN | |
---|---|
Cash Ratio | 2.46 |
Current Ratio | 2.89 |
Quick Ratio | 2.74 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
GERN | |
---|---|
ROA (LTM) | -30.30% |
ROE (LTM) | -69.03% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
GERN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
GERN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 81.61 |
P/B | 8.23 |
Price/FCF | NM |
EV/R | 73.05 |
EV/Ebitda | NM |
PEG | NM |
Geron Corporation (GERN) share price today is $3.92
Yes, Indians can buy shares of Geron Corporation (GERN) on Vested. To buy Geron Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in GERN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Geron Corporation (GERN) via the Vested app. You can start investing in Geron Corporation (GERN) with a minimum investment of $1.
You can invest in shares of Geron Corporation (GERN) via Vested in three simple steps:
The 52-week high price of Geron Corporation (GERN) is $5.34. The 52-week low price of Geron Corporation (GERN) is $1.64.
The price-to-earnings (P/E) ratio of Geron Corporation (GERN) is
The price-to-book (P/B) ratio of Geron Corporation (GERN) is 8.23
The dividend yield of Geron Corporation (GERN) is 0.00%
The market capitalization of Geron Corporation (GERN) is $2.41B
The stock symbol (or ticker) of Geron Corporation is GERN